Literature DB >> 22749121

Association of uric acid with mortality in patients with stable coronary artery disease.

Gjin Ndrepepa1, Siegmund Braun, Lamin King, Martin Hadamitzky, Hans-Ullrich Haase, Katrin Anette Birkmeier, Albert Schömig, Adnan Kastrati.   

Abstract

OBJECTIVE: The association between uric acid and cardiovascular disease is poorly studied. We undertook this study to assess whether uric acid level predicts clinical outcome in patients with stable coronary artery disease (CAD) treated with percutaneous coronary intervention (PCI). MATERIALS/
METHODS: This study included 8149 patients with stable CAD who underwent PCI. Uric acid was measured before angiography. The primary end point was 1-year mortality. Quartiles of quartiles of uric acid were: 1.49 to <5.49 mg/dl (1st quartile; n=2032 patients), 5.49 to <6.40 mg/dl (2nd quartile; n=1981 patients), 6.40 to <7.50 mg/dl (3rd quartile; n=2093 patients) and 7.50 to 21.90 mg/dl (4th quartile; n=2043 patients).
RESULTS: There were 196 deaths during the 1-year follow-up. The numbers of deaths (Kaplan-Meier estimates) according to uric acid quartiles were: 35 deaths (1.8%) in the 1st quartile, 30 deaths (1.6%) in the 2nd quartile, 45 deaths (2.2%) in the 3rd quartile and 86 deaths (4.3%) in the 4th quartile (unadjusted hazard ratio [HR]=1.60, 95% confidence interval [CI] 1.38-1.86, P<0.001 for each standard deviation [SD] increase in the logarithmic scale). After adjustment for traditional cardiovascular risk factors, renal function and inflammatory status, the association between uric acid and 1-year mortality remained significant (adjusted HR=1.26, 95% CI 1.07-1.48; P=0.005 for each standard deviation increase in the logarithmic scale). Uric acid improved predictivity of the multivariable model regarding mortality (P=0.040).
CONCLUSIONS: Elevated level of uric acid is an independent predictor of 1-year mortality in patients with stable CAD treated with PCI.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22749121     DOI: 10.1016/j.metabol.2012.05.014

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  14 in total

1.  Hyperuricemia is Associated with Increased Apo AI Fractional Catabolic Rates and Dysfunctional HDL in New Zealand Rabbits.

Authors:  Miriam Martínez-Ramírez; Cristóbal Flores-Castillo; L Gabriela Sánchez-Lozada; Rocío Bautista-Pérez; Elizabeth Carreón-Torres; José Manuel Fragoso; José Manuel Rodriguez-Pérez; Fernando E García-Arroyo; Victoria López-Olmos; María Luna-Luna; Gilberto Vargas-Alarcón; Martha Franco; Oscar Pérez-Méndez
Journal:  Lipids       Date:  2017-09-22       Impact factor: 1.880

Review 2.  Implications of the EMPA-REG Trial for Clinical Care and Research.

Authors:  Angeliki M Stamatouli; Silvio E Inzucchi
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

Review 3.  Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney
Journal:  Circulation       Date:  2017-10-24       Impact factor: 29.690

4.  Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein.

Authors:  Svetlana Krasnokutsky; Aaron Garza Romero; Daisy Bang; Virginia C Pike; Binita Shah; Talia F Igel; Irina Dektiarev; Yu Guo; Judy Zhong; Stuart D Katz; Michael H Pillinger
Journal:  Clin Rheumatol       Date:  2018-02-15       Impact factor: 2.980

Review 5.  Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors.

Authors:  Cezary Wojcik; Bruce A Warden
Journal:  Curr Cardiol Rep       Date:  2019-09-14       Impact factor: 2.931

Review 6.  SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.

Authors:  Silvio E Inzucchi; Bernard Zinman; Christoph Wanner; Roberto Ferrari; David Fitchett; Stefan Hantel; Rosa-Maria Espadero; Hans-Jürgen Woerle; Uli C Broedl; Odd Erik Johansen
Journal:  Diab Vasc Dis Res       Date:  2015-01-14       Impact factor: 3.291

7.  Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus.

Authors:  Yukihiro Bando; Hitomi Tohyama; Keiko Aoki; Hideo Kanehara; Azusa Hisada; Kazuhiro Okafuji; Daisyu Toya
Journal:  J Clin Transl Endocrinol       Date:  2016-06-16

8.  Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population.

Authors:  Jie Wu; Ling Qiu; Xin-Qi Cheng; Tao Xu; Wei Wu; Xue-Jun Zeng; Yi-Cong Ye; Xiu-Zhi Guo; Qian Cheng; Qian Liu; Li Liu; Cheng-Li Xu; Guang-Jin Zhu
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

Review 9.  Hyperuricemia and Hypertension, Coronary Artery Disease, Kidney Disease: From Concept to Practice.

Authors:  Mélanie Gaubert; Thomas Bardin; Alain Cohen-Solal; François Diévart; Jean-Pierre Fauvel; Régis Guieu; Stéphane Sadrin; Jean Michel Maixent; Michel Galinier; Franck Paganelli
Journal:  Int J Mol Sci       Date:  2020-06-06       Impact factor: 5.923

10.  Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.

Authors:  Young-Gun Kim; Seung Jin Han; Dae Jung Kim; Kwan-Woo Lee; Hae Jin Kim
Journal:  Cardiovasc Diabetol       Date:  2018-06-23       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.